Soluble urokinase-type plasminogen activator receptor
Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis
... decoy receptor 3 (DcR3), soluble urokinase type plasminogen activator receptor (suPAR) and procalcitonin (PCT) are significantly increased in ...
10
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
... increase. Soluble urokinase-type plasminogen activator receptor (suPAR) levels increase in acute viral and bacterial infections and in diseases involving chronic ...
9
The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
... However, there are some limitations of this study. Due to the fact that suPAR levels are also elevated due to co- morbidities, some of which have been mentioned above, it is considered a non-specific biomarker. Since ...
13
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease
... Background: Plasminogen activator inhibitor-1 (PAI-1) and soluble urokinase-type plasminogen activator receptor (suPAR) participate in inflammation and tissue remolding in vari[r] ...
8
Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria
... Plasma soluble urokinase–type plasminogen activator receptor (suPAR) reflects the systemic level of cell surface urokinase-type plasminogen activator ...
10
Soluble urokinase plasminogen activator receptor (suPAR) and natural phosphorylcholine IgM antibodies in patients at clinical onset of diabetes mellitus
... Figure 1. (a) shows plasma suPAR levels in controls and dia- betic subjects at clinical onset. Kruskal-Wallis H-test indicated a statistically significant difference between controls and pa- tients with diabetes mellitus ...
8
Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
... In the area of early diastolic dysfunction, hardly any study has looked at the association between suPAR and subclinical myocardial dysfunction. One recent study in- vestigated associations between suPAR and subclinical ...
7
Organization, evolution and functions of the human and mouse Ly6/uPAR family genes
... Ly6/urokinase-type plasminogen activator receptor-related protein 1 (SLURP1) is expressed in a variety of cells including immune cells [75], sensory neu- rons [76], and epithelial cells ...
19
Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor
... specific plasminogen activation/fibrinolysis during liver ...its receptor may optimize liver cell pro- liferation and repair, the primary functions of fibrin removal, clearance of necrotic cells, and ...
9
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
... the soluble urokinase-type plasminogen activator (uPA) receptor (suPAR) in approximately two-thirds of patients with FSGS, and suPAR levels were predictive of FSGS recur- rence ...
10
Role of Urokinase Receptor in Tumor Progression and Development
... Unlike normal tissues, uPAR level is constitu- tively increased in majority of cancer types including solid tumors, leukemia and lymphomas as well as in tumor-associated stromal cells such as fibroblasts and macrophages ...
9
Plasma soluble vascular endothelial growth factor receptor 1 levels predict outcomes of pneumonia related septic shock patients: a prospective observational study
... The role of uPA in the pathogenesis of sepsis is prob- ably complex. Through the conversion of plasminogen to plasmin, uPA may play an antithrombotic role in sep- sis. uPA also has pro-inflammatory effects, ...
11
Current insights into matrix metalloproteinases and glioma progression: transcending the degradation boundary
... glioma cells, yet it is a clear marker and effector of associ- ated protumor microglia. Therefore, observations of MMP14 on glioma cell lines in vitro likely do not replicate actual glioma cells in vivo. Nevertheless, ...
18
Common TNF α, IL 1β, PAI 1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis
... Wild type and mutant allele capture oligonucleotide probes (Table 1) were synthesized and modified at the 5' terminus (TAG Copenhagen, Denmark) and coupled to carboxylated microspheres as described by ...
7
Coordinated expression of the vitronectin receptor and the urokinase type plasminogen activator receptor in metastatic melanoma cells
... Integrin alpha v beta 3 is a marker of progression in malignant melanoma. Previously we reported that human melanoma cells derived from regional lymph node metastases had increased alpha v beta 3-mediated adhesion to ...
9
Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
... fibroblasts and cleaved u-PAR (D2D3) is increased in myofibroblasts [14]. The antibody used in our study was made for a C-terminal peptide present both on the intact and cleaved form of the receptor. Therefore, we ...
6
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
... nase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in fresh-frozen tumor tissue from primary breast cancers by a commercially available ...
9
Receptor-bound urokinase-type plasminogen activator in human colon cancer invasion and metastasis
... Statement Acknowledgements Abstract Abbreviations List of Figures CHAPTER 1 INTRODUCTION 1.1 Mechanisms of Tumour Invasion and Metastasis 1.1.1 Major steps in the process of metastasis 1[r] ...
250
Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy
... nano-precipitation strategy, fast aggregation during formulation often occurs, leading to large precipitates and low drug loading capacity. In order to avoid such phenomenon, we introduced the “structure defects” theory ...
14
Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
... Urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored protein. Besides regulating proteolysis, uPAR could also activate many ...
9